Promising pipeline CD47 antigen inhibitors such as IMC-002, MP 0621, HCB-101, PT-217, HX 009, Maplirpacept, IBI 322, ALX-148, HMPL-A83 and others are under different phases of CD47 antigen ...
Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug in solid tumours ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback